Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: March 2012

Chapter 31 - Organic acid, amino acids, and peroxisomal disorders

from Section 3 - Symptomatic epilepsy


The dentato-rubro-pallido-luysian atrophy (DRPLA) disorder was predominantly seen in the Japanese population. DRPLA is an autosomal dominant neurodegenerative disorder caused by abnormal repeat expansions within the DRPLA gene located on chromosome 12p13.31. Ataxia, choreoathetosis, and/or myoclonus and mental decline are the cardinal signs. Epileptic seizures usually occur in patients with an earlier onset. Unstable expanded CAG repeats in one allele in the DRPLA gene are responsible for this disorder and the size of the CAG expansion is well correlated with age of onset and severity of the disease. There are characteristic degeneration of both the dentato-rubral and pallido-luysian systems in the brain. Diffferential diagnosis includes all types of progressive myoclonic epilepsies, hereditary ataxia, and Huntington chorea. An autosomal dominant hereditary pattern and anticipation from the paternal side make the diagnosis more likely. However, a definitive diagnosis is based on genetic testing.


Applegarth DA, Toone JR (2004) Glycine encephalopathy (nonketotic hyperglycinaemia): review and update. J Inherit Metab Dis 27:417–22.
Baumgartner MR, Dantas MF, Suormala T, et al. (2004) Isolated 3-methylcrotonyl-CoA carboxylase deficiency: evidence for an allele-specific dominant negative effect and responsiveness to biotin therapy. Am J Hum Genet 75:790–800.
Biancheri R, Cerone R, Rossi A, et al. (2002) Early-onset cobalamin C/D deficiency: epilepsy and electroencephalographic features. Epilepsia 43:616–22.
Breton Martinez JR, Canovas Martinez A, Casana Perez S, et al. (2007) Mevalonic aciduria: report of two cases. J Inherit Metab Dis 30:829.
de Koning TJ (2006) Treatment with amino acids in serine deficiency disorders. J Inherit Metab Dis 29:347–51.
de Koning TJ, Klomp LW (2004) Serine-deficiency syndromes. Curr Opin Neurol 17:197–204.
de Koning TJ, Klomp LW, van Oppen AC, et al. (2004) Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 364:2221–2.
Desai S, Ganesan K, Hegde A (2008) Biotinidase deficiency: a reversible metabolic encephalopathy: neuroimaging and MR specroscopic findings in a series of four patients. Pediatr Radiol 38:848–56.
Fernandes J, Saudubray J-M, van den Berghe G (2000) Inborn Metabolic Diseases: Diagnosis and Treatment, 3rd edn. Heidelberg: Springer-Verlag.
Friebel D, Von Der Hagen M, Baumgartner ER, et al. (2006) The first case of 3-methylcrotonyl-CoA carboxylase (MCC) deficiency responsive to biotin. Neuropediatrics 37:72–8.
Gibson KM, Jacobs C, Ogier H, et al. (1995) Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis 18:143–6.
Guthrie R, Susi A (1963) A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338–43.
Häberle J, Görg B, Toutain A, et al. (2006) Inborn error of amino acid synthesis: human glutamine synthetase deficiency. J Inherit Metab Dis 29:352–8.
Hamosh A, Maher JF, Bellus GA, Rasmussen SA, Johnston MV (1998) Long-term use of high-dose benzoate and dextromethorphan for the treatment of nonketotic hyperglycinemia. J Pediatr 132:709–11.
Ito S, Nakayama T, Ide S, et al. (2008) Aromatic l-aminoacid decarboxylase deficiency associated with epilepsy mimicking non-epileptic involuntary movements. Dev Med Child Neurol 50:876–8.
Kalayci O, Coskun T, Tokatli A, et al. (1994) Infantile spasms as the initial symptom of biotinidase deficiency. J Pediatr 124:103–4.
Kölker S, Koeller DM, Sauer S, et al. (2004) Excitotoxicity and bioenergetics in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 27:805–12.
Kölker S, Sauer S, Surters RAM, et al. (2006) The aetiology of neurological complications of organic acidaemias: a role for the blood–brain barrier. J Inherit Metab Dis 29:701–4.
Kölker S, Sauer S, Hoffmann GF, et al. (2008) Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism. J Inherit Metab Dis 31:194–204.
Korman SH, Gutman A (2002) Pitfalls in the diagnosis of glycine encephalopathy (nonketotic hyperglycinemia). Dev Med Child Neurol 44:712–20.
Manegold C, Hoffmann GF, Degen I, et al. (2009) Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 32:371–80.
Molinari F, Raas-Rothschild A, Rio M, et al. (2005) Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet 76:334–9.
Neumaier-Probst E, Harting I, Seitz A, Ding C, Kolker S (2004) Neuroradiological findings in glutaric aciduria type I (glutaryl-CoA dehydrogenase deficiency). J Inherit Metab Dis 27:869–76.
Pearl PL (2009) New treatment paradigms in neonatal metabolic epilepsies. J Inherit Metab Dis 32:204–13.
Pearl PL, Novotny EJ, Acosta MT, Jakobs C, Gibson KM (2003) Succinic semialdehyde dehydrogenase deficiency in children and adults. Ann Neurol 54:S73–80.
Rzem R, Veiga-da-Cunha M, Noël G, et al. (2004) A gene encoding a putative FAD-dependent l-2-hydroxyglutarate dehydrogenase is mutated in l-2-hydroxyglutaric aciduria. Proc Natl Acad Sci USA 101:16 849–54.
Sauer SW, Okun JG, Fricker G, et al. (2006) Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids secondary to limited flux across the blood–brain barrier constitute a biochemical risk factor for neurodegeneration in glutaryl-CoA dehydrogenase deficiency. J Neurochem 97:899–910.
Scriver CR, Beaudet AL, Valle D, et al. (2001) The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill.
Steinberg SJ, Dodt G, Raymond GV, et al. (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta 1763:1733–48.
Struys EA, Salomons GS, Achouri Y, et al. (2005) Mutations in the d-2-hydroxyglutarate dehydrogenase gene cause d-2-hydroxyglutaric aciduria. Am J Hum Genet 76:358–60.
Tabatabaie L, de Koning TJ, Geboers AJ, et al. (2009) Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics. Hum Mutat 30:749–56.
Van der Knaap MS, Jacobs C, Hoffmann GF, et al. (1999) d-2-Hydroxyglutaric aciduria: further clinical delineation. J Inherit Metab Dis 22:404–13.
van Spronsen FJ, Hoeksma M, Reijngoud D-J (2009) Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause? J Inherit Metab Dis 32:46–51.
Veldman A, Santamaria-Araujo JA, Sollazzo S (2010) Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics 125:e1249–54.
Wajner M, Vargas CR, Funayama C, et al. (2002) d-2-Hydroxyglutaric aciduria in a patient with a severe clinical phenotype and unusual MRI findings. J Inherit Metab Dis 25:28–34.
Wanders RJ, Waterham HR (2006) Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta 1763:1707–20.
Wolf NI, Garcia-Cazorla A, Hoffmann GF (2009) Epilepsy and inborn errors of metabolism in children. J Inherit Metab Dis 32:609–17.
Zinnanti WJ, Lazovic J, Housman C, et al. (2007) Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type I. J Clin Invest 117:3258–70.